Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Send us all your questions or requests, and our expert team will assist you.
The Treatment and Management of hemophilia requires a coordinated approach that balances clotting factor replacement, preventive care, and lifestyle adjustments. This page is designed for patients, families, and caregivers seeking clear guidance on how hemophilia is treated worldwide, with a special focus on the comprehensive services available at Liv Hospital for international patients.
Hemophilia affects roughly 1 in 5,000 male births, making early diagnosis and ongoing care essential to prevent life‑threatening bleeding episodes. At Liv Hospital, multidisciplinary teams combine cutting‑edge therapies with personalized support, ensuring each patient receives a plan tailored to their severity, activity level, and personal goals.
Below you will find an in‑depth look at the various components of hemophilia treatment and management, from classic factor replacement to the newest gene‑therapy trials, as well as practical advice on daily living, travel, and emergency preparedness.
Hemophilia is classified primarily into two genetic forms: Hemophilia A (deficiency of factor VIII) and Hemophilia B (deficiency of factor IX). A less common variant, Hemophilia C, involves factor XI deficiency and is more prevalent in certain populations. Accurate diagnosis hinges on a combination of clinical history, family pedigree, and laboratory testing.
Key diagnostic steps include:
Early identification enables prompt initiation of therapy, which dramatically reduces joint damage and improves quality of life. At Liv Hospital, our hematology laboratory follows internationally recognized standards, ensuring rapid and reliable results for patients traveling from abroad.
The overarching aim of hemophilia treatment and management is to prevent bleeding, preserve joint function, and allow patients to lead active, unrestricted lives. These goals translate into three core objectives:
Clinicians develop individualized care plans based on disease severity (mild, moderate, severe), activity level, and patient preference. Regular assessments—typically every 3–6 months—allow the care team to adjust dosing schedules, introduce new therapies, and address any emerging complications such as inhibitor formation.
Prophylaxis, the routine administration of clotting factor concentrates, has become the standard of care for patients with severe hemophilia. By maintaining baseline factor levels, prophylactic regimens dramatically reduce the frequency of joint bleeds and long‑term arthropathy.
Common prophylactic products include:
Below is a comparison of traditional versus extended‑half‑life prophylaxis:
Parameter | Traditional Factor | Extended‑Half‑Life (EHL) Factor
|
|---|---|---|
Infusion Frequency | 2–3 times per week | Once weekly or less |
Peak Plasma Level | Rapid rise, short plateau | Higher, sustained plateau |
Patient Convenience | Higher burden | Reduced burden |
Cost Considerations | Generally lower per unit | Higher per unit but fewer infusions |
Liv Hospital’s hemophilia center offers individualized dosing calculators, home‑infusion training, and 24‑hour tele‑support to ensure patients adhere to their prophylactic schedules, regardless of where they reside
Despite optimal prophylaxis, breakthrough bleeds can occur, especially after trauma or surgery. On‑demand therapy focuses on rapid factor replacement to stop bleeding and minimize tissue damage.
Steps for effective on‑demand care:
For severe bleeds, especially intracranial or gastrointestinal, hospitals must have rapid access to high‑purity factor products and experienced hematologists. Liv Hospital maintains a dedicated emergency pathway for hemophilia patients, with stocked factor reserves, on‑site laboratory monitoring, and a multidisciplinary team ready to intervene within minutes.
Research in hemophilia is rapidly evolving, offering hope for curative approaches. Gene therapy, in particular, aims to introduce functional copies of the deficient factor gene, potentially providing long‑lasting clotting activity after a single infusion.
Current investigational modalities include:
Liv Hospital collaborates with leading academic centers and pharmaceutical sponsors, offering eligible patients access to Phase I/II trials. Participation includes comprehensive baseline assessments, close monitoring of liver function, and long‑term follow‑up to evaluate durability of response.
Effective treatment and management extends beyond medication. A holistic approach incorporates physical therapy, psychosocial counseling, and education to empower patients to make informed choices.
Key components of supportive care:
Liv Hospital’s International Patient Services team coordinates airport transfers, accommodation, and interpreter support, ensuring that patients from any country can receive seamless hemophilia care without language or logistical barriers.
Liv Hospital is a JCI‑accredited, internationally recognized center that combines world‑class hematology expertise with a dedicated 360‑degree patient service model. Our multidisciplinary team includes hematologists, surgeons, physiotherapists, and patient coordinators who work together to create individualized treatment and management plans. International patients benefit from streamlined appointment scheduling, multilingual interpreter assistance, and comfortable accommodation options, all designed to make complex medical journeys as smooth as possible.
Ready to take control of your hemophilia care? Contact Liv Hospital today to schedule a consultation with our specialist team and discover a personalized treatment pathway that fits your lifestyle.
Experience the confidence of world‑class care, supported every step of the way.
Liv Hospital Vadistanbul
Prof. MD. Itır Şirinoğlu Demiriz
Hematology
Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan
Pediatric Hematology and Oncology
Liv Hospital Bahçeşehir
Prof. MD. Yasemin Altuner Torun
Pediatric Hematology and Oncology
Liv Hospital Ankara
Assoc. Prof. MD. Ramazan Öcal
Hematology
Liv Hospital Ankara
Prof. MD. Meral Beksaç
Hematology
Liv Hospital Ankara
Prof. MD. Oral Nevruz
Hematology
Liv Hospital Gaziantep
Assoc. Prof. MD. Fadime Ersoy Dursun
Hematology
Spec. MD. Ceyda Aslan
Hematology
Spec. MD. Elmir İsrafilov
Hematology
Spec. MD. Minure Abışova Eliyeva
Hematology
Liv Hospital Ulus + Liv Hospital Bahçeşehir
Prof. MD. Mehmet Hilmi Doğu
Hematology
Send us all your questions or requests, and our expert team will assist you.
Currently, there is no definitive cure for hemophilia. However, modern treatments such as prophylactic factor replacement and emerging gene therapies allow the condition to be effectively managed. Gene therapy, in particular, shows promising potential for long-term or even lasting solutions.
Prophylactic therapy involves the regular administration of clotting factor concentrates to prevent bleeding episodes before they occur. It is especially important for patients with severe hemophilia, as it significantly reduces joint damage, lowers bleeding frequency, and improves overall quality of life.
At the first signs of bleeding—such as pain, swelling, or bruising—it is important to act quickly. The patient should immediately contact their healthcare provider and administer the prescribed clotting factor or bypassing agent as instructed. The affected area should be rested and, if appropriate, supported with gentle compression or immobilization. If the bleeding does not improve within a short period or appears severe, urgent medical care should be sought to prevent complications.
Yes. With proper treatment, regular monitoring, and appropriate lifestyle adjustments, individuals with hemophilia can lead active and fulfilling lives. Many can participate in school, work, and even sports with proper planning and medical guidance.
Gene therapy aims to introduce a functional copy of the missing or defective clotting factor gene into the body. This enables the patient’s body to produce the required clotting factor on its own, potentially providing long-term protection with a single treatment. However, it is still under clinical evaluation and not yet suitable for all patients.
BlogHematologyJun 05, 2026Our expert overview on low hb blood transfusion covers restrictive thresholds and personalized care to ensu...
BlogHematologyJun 05, 2026We explain low blood count causes, symptoms, and treatments. Our expert care supports patients worldwide fa...
BlogHematologyJun 05, 2026We guide you through low ANC count causes, risks, and treatments, helping you understand neutropenia and re...
BlogHematologyJun 05, 2026We explain low ANC, its impact on immune function, common causes like chemotherapy, and symptoms to watch f...
BlogHematologyJun 05, 2026We explain the life span of platelets, their production, and role in hemostasis to help manage bleeding dis...
BlogHematologyJun 05, 2026We explain leukocytes neutrophils high causes including infections, stress, and disorders, helping you unde...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 174 28 17